... “non-sensical.”

— Jim Greenwood of BIO, commenting on the possibility of a Senate bill creating a U.S. patent reform system which is modeled on, but broader than, the European Union’s processes, “Analysts say that patent reform will harm biotech, add costs,” pp. 1, 7.